Showing results (131-140 of 196) with videos related to
Sort By:
Pageof 20
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.Archives of Pathology & Laboratory Medicine|January 23, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
MET Exon 14-altered Lung Cancers and MET Inhibitor ResistanceRobin Guo, Michael Offin, A Rose Brannon, et al.European Urology Focus|July 30, 2017
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell CarcinomaBrandon John Manley, Emily C Zabor, Jozefina Casuscelli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2020
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung CancerAdam J Schoenfeld, Chai Bandlamudi, Jessica A Lavery, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2024
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable TargetsMonica F Chen, Soo-Ryum Yang, Jessica J Tao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian CancerBritta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.The Journal of Molecular Diagnostics : JMD|November 20, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow CytometryCaleb Ho, Mustafa Syed, Mikhail Roshal, et al.Cancer Discovery|October 18, 2023
Quantifying the Expanding Landscape of Clinical Actionability for Patients with CancerSarah P Suehnholz, Moriah H Nissan, Hongxin Zhang, et al.Pageof 20